Afya: UBS Upgrades to Buy from Neutral, PT Down to $19 from $19.5
ByAinvest
Monday, Sep 8, 2025 6:47 am ET1min read
AFYA--
The upgrade reflects Afya's consistent performance record, as the company has consistently met its guidance since its initial public offering in 2019. In the second quarter of 2025, Afya reported earnings per share (EPS) of $2.27, surpassing expectations by 14.65%. However, revenue fell short of projections at $919.4 million compared to the anticipated $935.49 million.
UBS highlighted Afya's impressive gross margins of ~65% and 15.6% revenue growth over the last twelve months. The company's stock experienced a modest increase despite the revenue shortfall, underscoring its financial resilience. Despite the stock's relatively low trading liquidity of approximately $2 million per day, UBS believes Afya presents an interesting risk/reward combo for investors who can manage the limited liquidity.
The new price target of $19.00 is based on a December 2026 outlook, compared to the previous December 2025 target of $19.50, offering a potential upside of 3.1% in dollar terms or 3.6% in Brazilian reais.
References:
[1] https://www.investing.com/news/analyst-ratings/jpmorgan-upgrades-afya-stock-rating-to-overweight-on-solid-performance-93CH-4228189
UBS--
Afya: UBS Upgrades to Buy from Neutral, PT Down to $19 from $19.5
UBS Group has upgraded Afya Ltd. (NASDAQ: AFYA) to "Buy" from "Neutral," lowering its price target to $19.00 from $19.50. The move follows the company's strong financial performance and solid earnings reports. Afya, a Brazilian education company, operates in a market with a $1.37 billion market capitalization.The upgrade reflects Afya's consistent performance record, as the company has consistently met its guidance since its initial public offering in 2019. In the second quarter of 2025, Afya reported earnings per share (EPS) of $2.27, surpassing expectations by 14.65%. However, revenue fell short of projections at $919.4 million compared to the anticipated $935.49 million.
UBS highlighted Afya's impressive gross margins of ~65% and 15.6% revenue growth over the last twelve months. The company's stock experienced a modest increase despite the revenue shortfall, underscoring its financial resilience. Despite the stock's relatively low trading liquidity of approximately $2 million per day, UBS believes Afya presents an interesting risk/reward combo for investors who can manage the limited liquidity.
The new price target of $19.00 is based on a December 2026 outlook, compared to the previous December 2025 target of $19.50, offering a potential upside of 3.1% in dollar terms or 3.6% in Brazilian reais.
References:
[1] https://www.investing.com/news/analyst-ratings/jpmorgan-upgrades-afya-stock-rating-to-overweight-on-solid-performance-93CH-4228189
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet